We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pramiracetam
A racetam-class nootropic structurally related to piracetam, promoted for memory and focus. Honest appraisal: the human evidence is very thin — essentially a couple of small, decades-old studies (one positive in head-injury patients, one largely unconvincing in Alzheimer's) plus a lot of anecdote. No modern, well-powered trials in healthy people.
What the evidence says
Pramiracetam doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from medium-quality randomised trials published 1985–1994 with a typical study size of 10 participants.
Based on 5 studies · 4 RCTs · 10 total participants
Confidence
Moderate confidenceBy outcome
Scores Emerging (2.5) because human evidence is limited to two small, decades-old trials and a review, with no modern controlled data in healthy adults.
Pramiracetam is a member of the racetam family (relatives of piracetam) marketed as a cognitive enhancer for memory and concentration.
Its proposed mechanism is poorly defined: like other racetams it lacks affinity for classical neurotransmitter receptors, and effects are attributed vaguely to enhanced hippocampal high-affinity choline uptake and potentiation of existing neurotransmission rather than any single well-characterized target.
The honest evidence picture is weak. The most-cited human result is a small 1991 double-blind placebo-controlled study in young men with memory deficits after head injury/anoxia, which reported clinically significant improvement in delayed recall.
A 1991 enrichment-design trial in 10 Alzheimer's patients was largely unconvincing — only 2 of 8 'best-dose' responders replicated, and the authors concluded benefit in Alzheimer's was unlikely.
Beyond these and a few comparative reviews, there is essentially no modern, adequately-powered randomized evidence — particularly none in healthy adults seeking cognitive enhancement. Most popular claims are anecdotal. The overall evidence is therefore low/emerging.
Increases sodium-dependent high-affinity choline uptake in rat hippocampal synaptosomes (animal/in-vitro); proposed to indirectly support cholinergic/memory function in humans.
Like other racetams, thought to modulate ion flux and potentiate already-present neurotransmission rather than bind a specific receptor.
How Pramiracetam works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Use caution — racetams are renally cleared.
Use caution due to theoretical platelet effects.
Not studied — avoid.
Racetams have been associated with effects on platelet aggregation; theoretical additive bleeding risk — use caution.
Racetams' cholinergic-leaning activity could be additive with cholinesterase inhibitors or other cholinergics.
Tip: Do not automatically add choline to treat a suspected adverse effect. New or persistent symptoms need assessment, with urgency determined by the symptoms.
Tip: Lower dose; dose earlier in the day
Tip: Avoid late-day dosing
Tip: Take with food
The current evidence for Pramiracetam is insufficient to assign an evidence score, based on 5 indexed studies. A racetam-class nootropic structurally related to piracetam, promoted for memory and focus. Honest appraisal: the human evidence is very thin — essentially a couple of small, decades-old studies (one positive in head-injury patients, one largely unconvincing in Alzheimer's) plus a lot of anecdote. No modern, well-powered trials in healthy people. Representative study: PMID 1786500.
Dosing for Pramiracetam: Commonly 400-1200mg/day in divided doses (no robustly validated regimen). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
The best time to take Pramiracetam is in the morning. Take it with food. Often taken in two or three divided doses earlier in the day; the head-injury trial used 400 mg three times daily.
Pramiracetam has a safety rating of "moderate". That is a category, not a measure of individual risk, and there are precautions worth knowing. Reported side effects include headache, nervousness / agitation, insomnia. How often they occur is not established for all of them. Use caution if any of these apply to you: Pregnancy/breastfeeding (not studied); Severe kidney impairment (renal clearance); Known hypersensitivity to racetams.
Huperzine A
Too few graded studiesAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Phosphatidylserine
Too few graded studiesKey brain membrane phospholipid that facilitates neurotransmitter release, memory formation, and post-exercise cortisol reduction.
Caffeine
Probably helpsBlocks adenosine receptors to boost alertness, reaction time, and endurance — an umbrella review of 21 meta-analyses found it ergogenic for endurance, strength and power.
Citicoline
Probably helpsPrecursor to acetylcholine and phosphatidylcholine. One trial in 100 healthy older adults improved memory. Stroke trials are mixed.
Explore: Best supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 5 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research